Manufacturing News of Note—Novartis to have Cell Therapies make Kymriah in Australia; Piramal Pharma expands API plant in Canada

A closeup of a stock market ticker
(Pixabay)

> After winning approval for public funding for its CAR-T drug Kymriah in Australia, Novartis announced an agreement for Australian CDMO Cell Therapies to manufacture the therapy in the country. Release  

> CDMO Piramal Pharma Solutions will invest $25 million to add a wing to its Aurora facility in Canada for API manufacturing. Release 

> A £50 million project has been completed to upgrade AstraZeneca’s warehousing, packing and logistics facilities at its site in Macclesfield, U.K. Story 

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

> Fresenius Kabi is investing €30 million to double the size of a transfusion and apheresis disposables plant in the Dominican Republic. Release  

> Bio-Techne and Wilson Wolf have joined Fresenius Kabi in a joint venture that will focus on providing scalable manufacturing technologies and processes for developing and commercializing cell and gene therapies. Release

Suggested Articles

Pfizer and BioNTech could have "millions" of doses of a potential COVID-19 vaccine ready to go this year if they start human testing this month.

Mylan will donate millions of doses of hydroxychloroquine "ahead of schedule" after ramping up production for the potential COVID-19 therapy.

President Trump's endorsement of hydroxychloroquine to treat COVID-19 has sent demand skyrocketing—and triggered a tussle with India.